Prognostic value of the ratio of pretreatment carcinoembryonic antigen to tumor volume in rectal cancer

• Published in: Journal of gastrointestinal oncology 2023-12, Vol.14 (6), p.2395-2408
• Main Authors: Zeng, Zhiming, Ma, Decai, Zhu, Pan, Niu, Kexin, Fu, Shuai, Di, Xiaohui, Zhu, Junying, Xie, Peiyi
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2078-6891; 2219-679X
• DOI: 10.21037/jgo-23-683

As a commonly used biomarker in rectal cancer (RC), the prognostic value of carcinoembryonic antigen (CEA) remains underexplored. This study aims to evaluate the prognostic value of pretreatment CEA/tumor volume in RC. This retrospective study included patients who underwent pretreatment magnetic resonance imaging (MRI) with histologically confirmed primary rectal adenocarcinoma from November 2012 to April 2018. Patients were divided into high-risk and low-risk groups according to the median values of CEA/Dia (CEA to pathological diameter), CEA/Dia (CEA to MRI tumor diameter), and CEA/Vol (CEA to MRI tumor volume). Cox regression analysis was utilized to determine the prognostic value of CEA, CEA/Dia , CEA/Dia , and CEA/Vol . Stepwise regression was used to establish nomograms for predicting disease-free survival (DFS) and overall survival (OS). Predictive performance was estimated by using the concordance index (C-index) and area under curve receiver operating characteristic (AUC). A total of 343 patients [median age 58.99 years, 206 (60.06%) males] were included. After adjusting for patient-related and tumor-related factors, CEA/Vol was superior to CEA, CEA/Dia , and CEA/Dia in distinguishing high-risk from low-risk patients in terms of DFS [hazard ratio (HR) =1.83; P=0.010] and OS (HR =1.67; P=0.048). Subanalysis revealed that CEA/Vol stratified high death risk in CEA-negative individuals (HR =2.50; P=0.038), and also stratified low recurrence risk in CEA-positive individuals (HR =2.06; P=0.024). In the subanalysis of stage II or III cases, the highest HRs and the smallest P values were observed in distinguishing high-risk from low-risk patients according to CEA/Vol in terms of DFS (HR =2.44; P=0.046 or HR =2.41; P=0.001) and OS (HR =1.96; P=0.130 or HR =2.22; P=0.008). The nomograms incorporating CEA/Vol showed good performance, with a C-index of 0.72 [95% confidence interval (CI): 0.68-0.79] for DFS and 0.73 (95% CI: 0.68-0.80) for OS. Higher CEA/Vol was associated with worse DFS and OS. CEA/Vol was superior to CEA, CEA/Dia , and CEA/Dia in predicting DFS and OS. Pretreatment CEA/Vol may facilitate risk stratification and treatment decision-making.